Knee Pain Articles & Analysis
25 news found
Cebranopadol is a novel, dual nociceptin/orphanin FQ peptide (NOP) receptor and μ-opioid peptide (MOP) receptor agonist in development for the treatment of moderate to severe pain. Multiple clinical studies have demonstrated that cebranopadol is efficacious in different types of pain. ...
We look forward to working closely with the FDA to expedite the review process for the NUsurface® Implant to provide a new treatment option to the hundreds of thousands of patients who continue to experience persistent knee pain following meniscus surgery, but are too young for total knee ...
Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery. “Current treatments for meniscus-related chronic ...
It has been estimated that from 700,000 to over 1 million partial meniscectomies are performed annually in the U.S. in an attempt to alleviate pain; however, recent studies have shown that many people who get a meniscectomy continue to experience pain that impacts their quality of life and can eventually lead to knee replacement surgery. ...
Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery. “There aren’t many great options for patients like ...
After suffering from excruciating knee pain, Art had a knee replacement with the TSolution One Total Knee Application. ...
With the installation of three KneeKG Systems, the project will demonstrate the functionalities and performance of Emovi’s AI Platform combined with its KneeKG technology to the military health system. “Knee pain affects one person out of five and includes sports injuries and structural diseases such as knee osteoarthritis ...
ByEmovi
KneeKGTM is the first in-clinic device that enables healthcare professionals to accurately, objectively, and in real-time assess a patient’s knee(s) in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the biomechanical and functional deficits linked to ...
ByEmovi
It has been estimated that over 2 million partial meniscectomies are performed annually worldwide in an attempt to alleviate pain; however, studies have shown that many people who get a meniscectomy continue to experience pain that impacts their quality of life and can eventually lead to knee replacement surgery. ...
The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint. It was granted a Breakthrough Device Designation from the FDA in 2019. ...
The HYALEX Cartilage System is intended to repair cartilage defects and restore function for patients with loss of knee articular cartilage and bone requiring surgery. Hyalex is currently in the pre-clinical stage of development with exceptional results to date and a world-class team working towards their first-in-human clinical study. ...
The technique is described as a Knee Kinesiography exam. “Knee pain is one of the most common complaints that physicians hear from patients,” says Dr. ...
ByEmovi
Global Phase IIb study to enrol approximately 312 patients, each of whom will receive one of three doses of MM-II or placebo Primary endpoint is a reduction in pain from baseline as measured by WOMAC A pain scale at 12 weeks Israel-based Moebius Medical today announced that the first patient has been dosed in its Phase IIb clinical trial of MM-II, a novel ...
” Continued Laflamme, “Through all of our studies, we have seen how a Knee Kinesiography with KneeKG can not only get athletes back to their sport more quickly after an injury, but the data derived can also pinpoint misalignments on a healthy knee and support efforts to prevent a knee injury altogether. ...
ByEmovi
The planned Phase IIb clinical trial, is a randomized, double-blind, dose-ranging, placebo-controlled study designed to determine the efficacy and safety of various doses of MM-II in subjects with symptomatic knee OA as compared to placebo. The primary endpoint is a reduction in pain from baseline as measured according to Western Ontario and McMaster ...
Rejoint provides the holistic approach for total knee replacement called YourKnee™ which has received the Conformité Européene (CE) Mark in January 2020. ...
Knee pain is the second leading cause of chronic pain. A knee pain survey revealed that 50 percent of Singaporean residents have previously or currently suffer from chronic knee pain and 73 percent are at risk of developing knee osteoarthritis in their lifetime, ...
ByEmovi
All of Intecore’s Physical Therapy locations – Aliso Viejo, CA; Foothill Ranch, CA; Orange, CA; San Juan Capistrano, CA and Bremerton, WA – will launch the KneeKG™ in their clinics this week. Knee pain is the second leading cause of chronic pain. One out of five people experiences knee ...
ByEmovi
Knee pain is the second leading cause of chronic pain. One out of five people experiences knee pain during their life due to an injury or pathology such as knee osteoarthritis, patellofemoral syndrome, ACL rupture, or a meniscal tear. The FDA cleared KneeKG is the first in-clinic device that ...
ByEmovi
KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a License and Supply Agreement with TRB Chemedica, a leading pharmaceutical and biotechnology company. KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a ...